Sugi Predict

Sugi Predict / Compounds / SCHEMBL747476

SCHEMBL747476

SCHEMBL747476

CC(=O)N1CCNC[C@@H]1C

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ DPP4 P27487 1/20 0.40
▸ CHRNB2 P17787 3/20 0.36
▸ CHRNA3 P32297 3/20 0.36
▸ CHRNA4 P43681 3/20 0.36
▸ CHRNB4 P30926 2/20 0.36
▸ PLD1 Q13393 1/20 0.36
▸ CHRNA7 P36544 1/20 0.34
▸ POLB P06746 1/20 0.32
▸ CHRNB3 Q05901 1/20 0.32
▸ CHRNA6 Q15825 1/20 0.32
▸ ENPP2 Q13822 1/20 0.32
▸ PAK4 O96013 4/20 0.32
▸ HTR6 P50406 1/20 0.31
▸ HTR2A P28223 1/20 0.31
▸ HTR2C P28335 1/20 0.31
▸ KHK P50053 1/20 0.31
▸ CHRM5 P08912 1/20 0.31
▸ CHRM3 P20309 1/20 0.31
▸ PAK1 Q13153 2/20 0.30
▸ CA12 O43570 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2321580 1.00 DPP4 (0.40) DPP4CHRNB2CHRNA3CHRNA4CHRNB4
SCHEMBL745860 1.00 DPP4 (0.40) DPP4CHRNB2CHRNA3CHRNA4CHRNB4
Hydrochloric Acid SCHEMBL3826687 0.98 DPP4 (0.39) DPP4CHRNB2CHRNA3CHRNA4CHRNB4
Hydrochloric Acid SCHEMBL640859 0.98 DPP4 (0.39) DPP4CHRNB2CHRNA3CHRNA4CHRNB4
Hydrochloric Acid SCHEMBL640860 0.98 DPP4 (0.39) DPP4CHRNB2CHRNA3CHRNA4CHRNB4
Trifluoroacetic Acid SCHEMBL26600110 0.88 DPP4 (0.38) DPP4CHRNB2CHRNA3CHRNA4CHRNB4
Trifluoroacetic Acid SCHEMBL26600122 0.88 DPP4 (0.38) DPP4CHRNB2CHRNA3CHRNA4CHRNB4
SCHEMBL28330960 0.85 DPP4 (0.41) DPP4CHRNB2CHRNA3CHRNA4PLD1
SCHEMBL27921094 0.85 DPP4 (0.41) DPP4CHRNB2CHRNA3CHRNA4PLD1
SCHEMBL2415913 0.83 DPP4 (0.40) DPP4CHRNB2CHRNA3CHRNA4PLD1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230340011-A1 STEROIDAL COMPOSITIONS AND METHODS OF TREATING LIPOGENIC CANCERS Asteroid Therapeutics 2023-10-26 — — US disclosed
US-20230340011-A1 STEROIDAL COMPOSITIONS AND METHODS OF TREATING LIPOGENIC CANCERS Asteroid Therapeutics 2023-10-26 — — US disclosed
WO-2021062246-A1 CRF RECEPTOR ANTAGONISTS AND METHODS OF USE NEUROCRINE BIOSCIENCES, INC. (US) 2021-04-01 — — WO disclosed
US-20160152615-A1 PRODRUGS OF SUBSTITUTED AZAINDOLEOXOACETIC PIPERAZINE DERIVATIVES VIIV HEALTHCARE UK (NO. 4) LIMITED (GB) 2016-06-02 — — US disclosed
EP-2430024-A1 [1,2,4]TRIAZOLO [4,3-B]PYRIDAZINES AS LIGANDS OF THE ANDROGEN RECEPTOR AstraZeneca AB (SE) 2012-03-21 — — EP disclosed
US-20110230497-A1 BIOLOGICALLY ACTIVE AMIDES H. LUNDBECK A/S (DK) 2011-09-22 — — US disclosed
EP-2352730-A2 BIOLOGICALLY ACTIVE AMIDES H. Lundbeck A/S (DK) 2011-08-10 — — EP disclosed
EP-2336132-A1 MORPHOLINOPURINE DERIVATIVE Daiichi Sankyo Company, Limited (JP) 2011-06-22 — — EP disclosed
WO-2010149684-A1 NEW COMPOUNDS, PHARMACEUTICAL COMPOSITION AND METHODS RELATING THERETO BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2010-12-29 — — WO disclosed
WO-2010131022-A1 [1,2,4] TRIAZOLO [4,3-B] PYRIDAZINES AS LIGANDS OF THE ANDROGEN RECEPTOR ASTRAZENECA AB (SE) 2010-11-18 — — WO disclosed
WO-2010131022-A1 [1,2,4] TRIAZOLO [4,3-B] PYRIDAZINES AS LIGANDS OF THE ANDROGEN RECEPTOR ASTRAZENECA AB (SE) 2010-11-18 — — WO disclosed
US-20100292222-A1 CHEMICAL COMPOUNDS 751 ASTRAZENECA AB (SE) 2010-11-18 — — US disclosed
US-20100292222-A1 CHEMICAL COMPOUNDS 751 ASTRAZENECA AB (SE) 2010-11-18 — — US disclosed
US-20100292222-A1 CHEMICAL COMPOUNDS 751 ASTRAZENECA AB (SE) 2010-11-18 — — US disclosed
WO-2010053861-A2 BIOLOGICALLY ACTIVE AMIDES H. LUNDBECK A/S (DK) 2010-05-14 — — WO disclosed
US-20090312310-A1 Imidazothiazole derivatives DAIICHI SANKYO COMPANY, LIMITED (JP) 2009-12-17 — — US disclosed
US-20090312310-A1 Imidazothiazole derivatives DAIICHI SANKYO COMPANY, LIMITED (JP) 2009-12-17 — — US disclosed
US-6291464-B1 POTENTIATION OF THE CHOLINERGIC ACTIVITY; THERAPEUTIC TREATMENT OF AMNESIA, DEMENTIA OR SENILE DEMENTIA FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2001-09-18 — — US disclosed
EP-0968201-A2 NEW AMINOPIPERAZINE DERIVATIVES FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2000-01-05 — — EP disclosed
WO-1998035951-A2 NEW AMINOPIPERAZINE DERIVATIVES FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1998-08-20 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160152615-A1 PRODRUGS OF SUBSTITUTED AZAINDOLEOXOACETIC PIPERAZINE DERIVATIVES ITPA, IMPDH2, IDO1 DPP4 131/4885CHRNB2 4643/4885CHRNA3 3961/4885
US-20100292222-A1 CHEMICAL COMPOUNDS 751 AR, NR5A1, KLK3 DPP4 3927/4885CHRNB2 1944/4885CHRNA3 1128/4885
US-20090312310-A1 Imidazothiazole derivatives TP53, MDM2, TP53BP1 DPP4 2929/4885CHRNB2 4675/4885CHRNA3 4603/4885
US-20110230497-A1 BIOLOGICALLY ACTIVE AMIDES NPY5R, NPY1R, NPY2R DPP4 1018/4885CHRNB2 450/4885CHRNA3 330/4885
US-20230340011-A1 STEROIDAL COMPOSITIONS AND METHODS OF TREATING LIPOGENIC CANCERS SREBF1, SREBF2, NR1H3 DPP4 3516/4885CHRNB2 4553/4885CHRNA3 4560/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.